JP2021138755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021138755A5 JP2021138755A5 JP2021098226A JP2021098226A JP2021138755A5 JP 2021138755 A5 JP2021138755 A5 JP 2021138755A5 JP 2021098226 A JP2021098226 A JP 2021098226A JP 2021098226 A JP2021098226 A JP 2021098226A JP 2021138755 A5 JP2021138755 A5 JP 2021138755A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- unsubstituted
- above formula
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(C(C)*)*(C)*C(IC(CC1)CCC1OCC)=C Chemical compound CCC(C(C)*)*(C)*C(IC(CC1)CCC1OCC)=C 0.000 description 37
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- QRMPKOFEUHIBNM-UHFFFAOYSA-N CC1CCC(C)CC1 Chemical compound CC1CCC(C)CC1 QRMPKOFEUHIBNM-UHFFFAOYSA-N 0.000 description 2
- MQWCXKGKQLNYQG-UHFFFAOYSA-N CC(CC1)CCC1O Chemical compound CC(CC1)CCC1O MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 1
Claims (7)
- 式(IB)の化合物、または、当該化合物の、薬学的に許容可能な塩、互変異性体、立体異性体、鏡像異性体もしくはアイソトポログ
R 4 は、置換もしくは無置換のC 1−8 アルキル、または置換もしくは無置換の非芳香族性ヘテロサイクリルである;
但し、当該化合物は、
4−(イソペンチルアミノ)−2−(3−(2−メチルピペリジン−1−イル)プロピルアミノ)ピリミジン−5−カルボニトリル;
(2S,2’S)−ジメチル−2,2’−(5−シアノピリミジン−2,4−ジイル)ビス(アザンジイル)ビス(4−メチルペンタノエート);
(2S,2’S)−ジエチル−2,2’−(5−シアノピリミジン−2,4−ジイル)ビス(アザンジイル)ビス(3−メチルブタノエート);
4−(シクロヘプチルアミノ)−2−(3−(2−メチルピペリジン−1−イル)プロピルアミノ)ピリミジン−5−カルボニトリル;
4−(4−メチルシクロヘキシルアミノ)−2−(3−(2−メチルピペリジン−1−イル)プロピルアミノ)ピリミジン−5−カルボニトリル;および
2−(3−(ジエチルアミノ)プロピルアミノ)−4−(4−メチルシクロヘキシルアミノ)ピリミジン−5−カルボニトリルではない)
の、間質性肺線維症;全身性硬化症;強皮症;慢性移植腎症;抗体を介した拒絶反応;または狼瘡の治療または予防のための薬学的組成物の調製における、使用。 - 上記式(IB)の化合物は、R 3 が分枝状のC 1−8 アルキルである、請求項1に記載の使用。
- 上記式(IB)の化合物は、R 3 が置換または無置換のシクロアルキルである、請求項1に記載の使用。
- 上記式(IB)の化合物は、R 3 が置換または無置換の非芳香族性ヘテロサイクリルである、請求項1に記載の使用。
- 上記式(IB)の化合物は、R 4 が置換または無置換のC 1−8 アルキルである、請求項1に記載の使用。
- 上記式(IB)の化合物は、R 4 が置換または無置換の非芳香族性ヘテロサイクリルである、請求項1に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023183330A JP2023179797A (ja) | 2011-04-22 | 2023-10-25 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478076P | 2011-04-22 | 2011-04-22 | |
US61/478,076 | 2011-04-22 | ||
US201161555339P | 2011-11-03 | 2011-11-03 | |
US61/555,339 | 2011-11-03 | ||
JP2019052826A JP6898961B2 (ja) | 2011-04-22 | 2019-03-20 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019052826A Division JP6898961B2 (ja) | 2011-04-22 | 2019-03-20 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023183330A Division JP2023179797A (ja) | 2011-04-22 | 2023-10-25 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021138755A JP2021138755A (ja) | 2021-09-16 |
JP2021138755A5 true JP2021138755A5 (ja) | 2021-12-16 |
JP7374955B2 JP7374955B2 (ja) | 2023-11-07 |
Family
ID=46025954
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014506559A Active JP6027095B2 (ja) | 2011-04-22 | 2012-04-20 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
JP2016202099A Active JP6502302B2 (ja) | 2011-04-22 | 2016-10-13 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
JP2019052826A Active JP6898961B2 (ja) | 2011-04-22 | 2019-03-20 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
JP2021098226A Active JP7374955B2 (ja) | 2011-04-22 | 2021-06-11 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
JP2023183330A Pending JP2023179797A (ja) | 2011-04-22 | 2023-10-25 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014506559A Active JP6027095B2 (ja) | 2011-04-22 | 2012-04-20 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
JP2016202099A Active JP6502302B2 (ja) | 2011-04-22 | 2016-10-13 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
JP2019052826A Active JP6898961B2 (ja) | 2011-04-22 | 2019-03-20 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023183330A Pending JP2023179797A (ja) | 2011-04-22 | 2023-10-25 | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 |
Country Status (33)
Country | Link |
---|---|
US (7) | US9139534B2 (ja) |
EP (2) | EP2699553B1 (ja) |
JP (5) | JP6027095B2 (ja) |
KR (2) | KR101962488B1 (ja) |
CN (5) | CN105001165B (ja) |
AR (1) | AR087151A1 (ja) |
AU (1) | AU2012245387C1 (ja) |
BR (1) | BR112013022813B1 (ja) |
CA (1) | CA2829264C (ja) |
CL (1) | CL2013003025A1 (ja) |
CO (1) | CO6821941A2 (ja) |
CR (1) | CR20130490A (ja) |
DK (1) | DK2699553T3 (ja) |
EC (1) | ECSP13012985A (ja) |
FI (1) | FI2699553T3 (ja) |
HR (1) | HRP20240097T1 (ja) |
HU (1) | HUE064883T2 (ja) |
IL (3) | IL228721A (ja) |
LT (1) | LT2699553T (ja) |
MX (1) | MX351754B (ja) |
NI (1) | NI201300113A (ja) |
PE (1) | PE20140502A1 (ja) |
PH (1) | PH12015501677B1 (ja) |
PL (1) | PL2699553T3 (ja) |
PT (1) | PT2699553T (ja) |
RS (1) | RS65202B1 (ja) |
RU (2) | RU2625309C2 (ja) |
SG (2) | SG10201702654VA (ja) |
SI (1) | SI2699553T1 (ja) |
TW (3) | TWI548621B (ja) |
UA (1) | UA120740C2 (ja) |
WO (1) | WO2012145569A1 (ja) |
ZA (1) | ZA201306471B (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI548621B (zh) * | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
EP2917186B1 (en) * | 2012-11-08 | 2017-10-18 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn |
US9447026B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
CN104262328B (zh) * | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
US10189780B2 (en) | 2013-12-12 | 2019-01-29 | Zeno Royalties & Milestones, LLC | Bicyclic alkyl compounds and synthesis |
MX2016007898A (es) * | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
CN106232567B (zh) | 2014-03-07 | 2021-11-02 | 里科瑞尔姆Ip控股有限责任公司 | 螺桨烷衍生物及合成 |
EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
EA033530B1 (ru) | 2014-12-16 | 2019-10-31 | Signal Pharm Llc | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида |
JP6903577B2 (ja) * | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
WO2016123291A1 (en) * | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
WO2018019244A1 (zh) * | 2016-07-27 | 2018-02-01 | 广东东阳光药业有限公司 | 2,6-二甲基嘧啶酮衍生物的盐及其用途 |
WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
WO2018049353A1 (en) * | 2016-09-12 | 2018-03-15 | Imago Pharmaceuticals, Inc. | Treatment of fibrotic disorders with jun n-terminal kinase inhibitors |
US20180243263A1 (en) | 2016-12-09 | 2018-08-30 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
CA3063729A1 (en) | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Analgesic compounds |
MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
CN107573249B (zh) * | 2017-09-25 | 2018-12-25 | 上海馨远医药科技有限公司 | 一种反式4-烷氧基环己胺的制备方法 |
WO2019089667A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
WO2020187292A1 (zh) * | 2019-03-19 | 2020-09-24 | 北京赛特明强医药科技有限公司 | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 |
CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
CN114364659A (zh) * | 2019-08-06 | 2022-04-15 | 伊莱利利公司 | 嘧啶-5-甲酰胺化合物 |
CN112574123A (zh) * | 2019-09-30 | 2021-03-30 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
KR20220151617A (ko) * | 2020-03-06 | 2022-11-15 | 내셔날 헬스 리서치 인스티튜트 | 피리미딘 화합물 및 이의 약학적 용도 |
WO2022048684A1 (zh) * | 2020-09-07 | 2022-03-10 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
US20230416225A1 (en) * | 2020-11-09 | 2023-12-28 | Merck Sharp & Dohme Llc | Diaminopyrimidine carboxamide inhibitors of hpk1 |
EP4294784A1 (en) * | 2021-02-22 | 2023-12-27 | The Trustees of Princeton University | 2-substituted bicyclo[1.1.1]pentanes |
WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
CN114315738B (zh) * | 2022-01-15 | 2023-08-18 | 重庆东寰科技开发有限公司 | 一种2,4-二氨基嘧啶-3-氧化物的制备方法 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH549339A (de) | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
US4301281A (en) * | 1979-04-18 | 1981-11-17 | American Home Products Corporation | 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]-pyrimidine-6-carboxylic acid amides |
DE3338859A1 (de) * | 1983-10-26 | 1985-05-09 | Bayer Ag, 5090 Leverkusen | Substituierte pyrimidine |
EP1054004B1 (en) * | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
ID27589A (id) | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
JP4622047B2 (ja) | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
EP1184376B1 (en) * | 1999-06-09 | 2005-02-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
WO2000076980A1 (fr) | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
JPWO2003082855A1 (ja) * | 2002-03-28 | 2005-08-04 | 協和醗酵工業株式会社 | 抗炎症剤 |
US20060046992A1 (en) | 2002-06-25 | 2006-03-02 | Kyowa Hakko Kogyo Co., Ltd. | Heterobicyclic compounds |
MXPA04012855A (es) * | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
BR0315897A (pt) * | 2002-11-01 | 2008-05-13 | Abbott Lab | agentes antiinfecciosos |
US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
AU2003289330A1 (en) | 2002-12-13 | 2004-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
WO2004067516A1 (en) * | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
EP1615928A1 (en) * | 2003-04-10 | 2006-01-18 | F.Hoffmann-La Roche Ag | Pyrimido compounds |
EP1518655A1 (en) * | 2003-07-24 | 2005-03-30 | John Palmer Corp. | Apparatus for and process of gas-assisted injection molding of plastics material |
MY147449A (en) | 2003-08-15 | 2012-12-14 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
AU2004275733A1 (en) | 2003-09-24 | 2005-04-07 | Wyeth Holdings Corporation | 5-arylpyrimidines as anticancer agents |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
WO2006014482A1 (en) * | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
CA2579007A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Ciclesonide and syk inhibitor combination and methods of use thereof |
WO2006027378A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Roflumilast and syk inhibitor combination and methods of use thereof |
JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
CN101027288B (zh) | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
WO2006099231A1 (en) | 2005-03-10 | 2006-09-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
MX2008002385A (es) * | 2005-08-25 | 2008-03-18 | Hoffmann La Roche | Inhibidores de proteinas cinasas activads por mitogenos p38 y metodos para utilizarlos. |
WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
WO2007076247A1 (en) | 2005-12-21 | 2007-07-05 | Boehringer Ingelheim International Gmbh | Pyrimidine derivatives useful as inhibitors of pkc-theta |
BRPI0715418A2 (pt) * | 2006-07-21 | 2013-03-26 | Novartis Ag | compostos de 2,4-di(arilaminio)-pirimidina-5-carboxamida como inibidores de cinases jak |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
CN101678215B (zh) | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
RU2009143753A (ru) | 2007-04-27 | 2011-06-10 | Астразенека Аб (Se) | Производные n'-(фенил)-n-(морфолин-4-ил-пиридин-2-ил)-пиримидин-2, 4-идиамина в качестве ингибиторов ернв4 киназы для лечения пролиферативных состояний |
AU2008277446A1 (en) | 2007-07-16 | 2009-01-22 | Astrazeneca Ab | Pyrimidine derivatives 934 |
CA2693594A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
KR20170051521A (ko) * | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
US8063058B2 (en) * | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
KR101623997B1 (ko) * | 2008-04-16 | 2016-05-24 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
CA2719936A1 (en) | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CN102015704A (zh) | 2008-04-29 | 2011-04-13 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US20110159019A1 (en) | 2008-09-01 | 2011-06-30 | Akira Tanaka | 2,4-diaminopyrimidine compound |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
EP2331507A2 (en) | 2008-09-18 | 2011-06-15 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
CN102177161A (zh) * | 2008-10-22 | 2011-09-07 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
BRPI0919885A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
EP2375899B1 (en) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
BRPI1006162A2 (pt) | 2009-01-13 | 2019-09-24 | Glaxo Group Ltd | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". |
EP2389373B1 (en) * | 2009-01-21 | 2017-05-17 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
JP2012148977A (ja) * | 2009-05-20 | 2012-08-09 | Astellas Pharma Inc | アミノシクロヘキシルアルキル基を有する2,4−ジアミノピリミジン化合物 |
AU2010258937A1 (en) * | 2009-06-08 | 2012-01-19 | Reduction Technologies Inc. | Systems, methods and devices for correcting spinal deformities |
EP2440548A1 (en) | 2009-06-10 | 2012-04-18 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ttk阻害作用を有するピリジンおよびピリミジン誘導体 |
WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
EP2507227B1 (en) | 2009-12-01 | 2014-10-08 | Rigel Pharmaceuticals, Inc. | Tetrazolones as protein kinase c inhibitors and uses thereof |
JP2011173853A (ja) | 2010-02-26 | 2011-09-08 | Astellas Pharma Inc | 置換アミノアダマンチルアルキル基を有する2,4−ジアミノピリミジン化合物 |
CA2801781C (en) | 2010-07-21 | 2018-02-27 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
EP2621489A1 (en) | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
WO2012044936A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
TWI548621B (zh) * | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
MX2016007898A (es) * | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
JP6903577B2 (ja) * | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
EA033530B1 (ru) * | 2014-12-16 | 2019-10-31 | Signal Pharm Llc | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида |
-
2012
- 2012-04-20 TW TW101114317A patent/TWI548621B/zh active
- 2012-04-20 SG SG10201702654VA patent/SG10201702654VA/en unknown
- 2012-04-20 EP EP12718524.7A patent/EP2699553B1/en active Active
- 2012-04-20 HR HRP20240097TT patent/HRP20240097T1/hr unknown
- 2012-04-20 AU AU2012245387A patent/AU2012245387C1/en active Active
- 2012-04-20 CN CN201510389071.XA patent/CN105001165B/zh active Active
- 2012-04-20 WO PCT/US2012/034349 patent/WO2012145569A1/en active Application Filing
- 2012-04-20 PT PT127185247T patent/PT2699553T/pt unknown
- 2012-04-20 FI FIEP12718524.7T patent/FI2699553T3/fi active
- 2012-04-20 PL PL12718524.7T patent/PL2699553T3/pl unknown
- 2012-04-20 CA CA2829264A patent/CA2829264C/en active Active
- 2012-04-20 KR KR1020137027371A patent/KR101962488B1/ko active IP Right Grant
- 2012-04-20 EP EP23205984.0A patent/EP4328223A2/en active Pending
- 2012-04-20 CN CN201280019861.3A patent/CN103492370B/zh active Active
- 2012-04-20 SI SI201232053T patent/SI2699553T1/sl unknown
- 2012-04-20 BR BR112013022813A patent/BR112013022813B1/pt active IP Right Grant
- 2012-04-20 TW TW105112041A patent/TWI599563B/zh active
- 2012-04-20 US US13/451,574 patent/US9139534B2/en active Active
- 2012-04-20 RU RU2013152021A patent/RU2625309C2/ru active
- 2012-04-20 CN CN202010398710.XA patent/CN111471021B/zh active Active
- 2012-04-20 CN CN201610882236.1A patent/CN106946795B/zh active Active
- 2012-04-20 KR KR1020197007112A patent/KR102055532B1/ko active IP Right Grant
- 2012-04-20 UA UAA201313555A patent/UA120740C2/uk unknown
- 2012-04-20 LT LTEPPCT/US2012/034349T patent/LT2699553T/lt unknown
- 2012-04-20 SG SG2013074273A patent/SG194086A1/en unknown
- 2012-04-20 PE PE2013002388A patent/PE20140502A1/es active IP Right Grant
- 2012-04-20 DK DK12718524.7T patent/DK2699553T3/da active
- 2012-04-20 RU RU2017121958A patent/RU2697712C2/ru active
- 2012-04-20 TW TW106120278A patent/TWI681952B/zh active
- 2012-04-20 HU HUE12718524A patent/HUE064883T2/hu unknown
- 2012-04-20 JP JP2014506559A patent/JP6027095B2/ja active Active
- 2012-04-20 MX MX2013010946A patent/MX351754B/es active IP Right Grant
- 2012-04-20 CN CN202010398589.0A patent/CN111499580A/zh active Pending
- 2012-04-20 RS RS20240075A patent/RS65202B1/sr unknown
- 2012-04-23 AR ARP120101402 patent/AR087151A1/es active IP Right Grant
-
2013
- 2013-08-28 ZA ZA2013/06471A patent/ZA201306471B/en unknown
- 2013-09-26 CR CR20130490A patent/CR20130490A/es unknown
- 2013-10-03 IL IL228721A patent/IL228721A/en active IP Right Grant
- 2013-10-08 CO CO13238970A patent/CO6821941A2/es active IP Right Grant
- 2013-10-18 CL CL2013003025A patent/CL2013003025A1/es unknown
- 2013-10-21 NI NI201300113A patent/NI201300113A/es unknown
- 2013-10-21 EC ECSP13012985 patent/ECSP13012985A/es unknown
-
2015
- 2015-07-29 PH PH12015501677A patent/PH12015501677B1/en unknown
- 2015-07-31 US US14/814,633 patent/US9701643B2/en active Active
-
2016
- 2016-05-23 IL IL245792A patent/IL245792B/en active IP Right Grant
- 2016-10-13 JP JP2016202099A patent/JP6502302B2/ja active Active
-
2017
- 2017-06-07 US US15/616,039 patent/US10040770B2/en active Active
- 2017-06-15 IL IL252952A patent/IL252952B/en active IP Right Grant
-
2018
- 2018-06-28 US US16/021,415 patent/US10266500B2/en active Active
-
2019
- 2019-03-04 US US16/291,193 patent/US10919865B2/en active Active
- 2019-03-20 JP JP2019052826A patent/JP6898961B2/ja active Active
-
2020
- 2020-12-29 US US17/136,276 patent/US11325890B2/en active Active
-
2021
- 2021-06-11 JP JP2021098226A patent/JP7374955B2/ja active Active
-
2022
- 2022-03-29 US US17/707,471 patent/US20230116093A1/en active Pending
-
2023
- 2023-10-25 JP JP2023183330A patent/JP2023179797A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021138755A5 (ja) | ||
RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
JP2015524443A5 (ja) | ||
JP2013523733A5 (ja) | ||
JP2012502974A5 (ja) | ||
JP2013517283A5 (ja) | ||
RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
JP2018535999A5 (ja) | ||
JP2013530240A5 (ja) | ||
JP2017524026A5 (ja) | ||
JP2014526549A5 (ja) | ||
PE20091891A1 (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
JP2008513516A5 (ja) | ||
HRP20160287T1 (hr) | Antagonisti cgrp receptora | |
JP2009501745A5 (ja) | ||
JP2014511891A5 (ja) | ||
JP2009504792A5 (ja) | ||
RU2017126187A (ru) | 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита | |
JP2012507535A5 (ja) | ||
JP2015531774A5 (ja) | ||
JP2013517279A5 (ja) | ||
JP2020503293A5 (ja) | ||
JP2013505949A5 (ja) | ||
JP2020503292A5 (ja) | ||
JP2020503295A5 (ja) |